Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...